Enabling genomics to eliminate the waste of life caused by infectious disease

Homepage Banners (34)

Our Mission

To improve global health by developing an “Always On” pathogen detection and monitoring system.

Managing the growing threat from Infectious Diseases and AMR is one of the greatest challenges of our time

Climate change, rapid urbanisation, global travel, and changing land use are dramatically increasing the risk of emerging infectious diseases.

Between 2025 and 2050, 39 million lives are forecast to be lost to antimicrobial resistance (AMR)—equivalent to the population of Canada (source: University of Oxford).
Additionally, there is a 27.5% probability of a pandemic occurring within the next 5 years, putting millions of lives and trillions of dollars at risk (source: Airfinity).

EIT Pathogena are targeting the millions of lives lost through the inappropriate treatment of infectious diseases and the avoidable escalation from local outbreaks to pandemics.

Quote_2_homepage

Our Purpose

To develop a global, ‘Always-On’ pathogen monitoring ecosystem that will revolutionise infectious disease prevention and treatment. We will be able to predict and prevent future pandemics, advance precision medicine and develop point-of-care diagnostics to improve outcomes and save lives.

Our Approach

Central to this mission is our belief in collaborative science, a deep commitment to developing authentic, interdisciplinary partnerships among clinicians, researchers, academics, and governments worldwide.

Collaborate with us
Globe new

Our first step

In partnership with the University of Oxford, globally renowned for their expertise in pathogens, and Oracle, world leaders in cloud data management, we have delivered an industry leading, fully automated genomic analysis platform with secure, scalable cloud data management.

EIT Pathogena’s Bioinformatic Analysis Platform

EIT Pathogena’s Bioinformatic Analysis Platform

Untitled design
Mycobacteria
The Mycobacterium analysis includes species identification, lineage calling, identification of related isolates of Mycobacterium tuberculosis complexes and resistance prediction to 15 drugs. The pipeline can also analyse 190 non-tuberculous mycobacteria (NTMs).

Its many features and advantages include; human read removal, the transformational speed of its complete analysis & alignment to the WHO V2 catalogue.

Supported NGS Technologies: Illumina and Oxford Nanopore Technologies (experimental)

Discover

SARS-CoV-2

The SARS-CoV-2 analysis includes consensus genome assembly, pangolin lineage assignment, and identification of related isolates, for SARS-CoV-2 sequenced using tiled amplicon sequencing.

Its features and benefits include human read removal, the transformational speed of its complete analysis & phylogenetic relatedness.

Supported Technologies: Illumina and Oxford Nanopore Technologies.

Discover

Driving Innovation in Pathogen Research

We are building a comprehensive, end-to-end technology ecosystem which can be sustainably integrated within routine clinical practice and public health systems and deliver the ‘Always On’ mission.

The Data Platform is a foundational element to this mission, a transformative resource that unlocks new possibilities in infectious disease research and innovation. By addressing barriers such as limited data access, fragmented data sharing, and insufficient computational power, the Data Platform will empower researchers to perform advanced analyses, develop cutting-edge algorithms, and gain deeper insights into pathogens.

The Data Platform will support efforts to revolutionise the diagnosis and treatment of infectious diseases. It will enable real-time, scalable responses to outbreaks and drive the development of continuous, point-of-care diagnostics and surveillance systems that accelerate improvements in global health outcomes.

It will provide access to valuable, anonymised datasets for independent researchers, collaborative networks, and third-party organisations, under robust scientific and ethical oversight. The Data Platform will deliver the tools and infrastructure needed to advance science and shape a future where pathogen detection and response are seamless, efficient, and impactful.

Professor Sir John Bell

Professor Sir John Bell

President EIT Oxford
"Pathogena is a company with substantial finance and commitment from the Ellison Institute for Technology. It has the potential to solve the global problem of rapid diagnosis of infectious diseases and detection of new pathogens."